407 results on '"Foster Rs"'
Search Results
2. Species and space: role of volume in organizing coral reef fish assemblages in SE Cuba
- Author
-
Balasubramanian, H, primary and Foster, RS, additional
- Published
- 2007
- Full Text
- View/download PDF
3. Molecular genetic evidence supporting the neoplastic nature of stromal cells in ‘fibrosis’ after chemotherapy for testicular germ cell tumours
- Author
-
Cheng, L, primary, Zhang, S, additional, Wang, M, additional, Davidson, DD, additional, Morton, MJ, additional, Huang, J, additional, Zheng, S, additional, Jones, TD, additional, Beck, SD, additional, and Foster, RS, additional
- Published
- 2007
- Full Text
- View/download PDF
4. Medicare financial status, budget impact, and sustainability -- which concept is which?
- Author
-
Foster RS and Clemens MK
- Abstract
Medicare is continually undergoing change, as it must in order to reflect advances in medical technology, new health care delivery systems, financial pressures, and other developments. Modifications to the program are debated by policymakers in Congress and the administration, together with academic experts and others. These debates would be improved if policymakers and the public had a clearer understanding of Medicare and certain commonly cited views of the program's overall status. Three such concepts-the financial status of the Medicare trust funds, the impact of Medicare on the Federal budget, and the long-run sustainability of Medicare-are often confused with each other and are sometimes used interchangeably. Each concept is important but needs to be used for its own purpose. This article clarifies the differences among these three views of Medicare and provides examples of each. [ABSTRACT FROM AUTHOR]
- Published
- 2009
5. Treating stage 1 testis cancer: should laparoscopic RPLND replace open RPLND as the standard of care?
- Author
-
Loughlin KR, Orvieto M, Shalhar AL, and Foster RS
- Abstract
Open RPLND has been the standard for staging and treating patients with clinical stage 1 NSGCTs. Is laparoscopic RPLND merely an 'expensive staging tool' or can it deliver comparable cancer control to the open procedure? Experts from Indiana University and the University of Chicago discuss and debate the advantages and disadvantages of these surgical approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2006
6. Testis cancer: controversies and options.
- Author
-
Richie JP, Einhorn LH, Foster RS, Jewett MAS, and Studer UE
- Abstract
Cooperation between radiation therapists, medical oncologists, and surgeons has made testis cancer one of the most curable of all solid malignancies. In this 2-part symposium, a distinguished panel of experts examines the variety of modalities available to treat testis cancer and addresses several controversies about how best to manage this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2001
7. Testis cancer: options in the land of plenty.
- Author
-
Richie JP, Einhorn LH, Foster RS, Jewett MAS, and Studer UE
- Abstract
Our panel was assembled to discuss and debate a variety of topics related to testis cancer, including the value of staging studies, how to define risk of relapse, and options for managing both seminomatous and nonseminomatous tumor by stage of disease and risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2001
8. The financial status of Medicare.
- Author
-
Foster RS
- Abstract
Medicare is the largest health care program in the country, providing medical care to 38 million aged and disabled Americans. Concerns over rapid cost increases and the imminent insolvency of the Medicare Hospital Insurance trust fund led to enactment of sweeping Medicare legislation as part of the Balanced Budget Act of 1997. Preliminary estimates indicate that this legislation will result in program savings of $150 billion in the first five years and will postpone the depletion of the Hospital Insurance fund from the year 2001 until about 2010. While the Balanced Budget Act significantly reduces Hospital Insurance expenditures in the long range, serious deficits are still expected when the 'baby boom' generation reaches retirement. The Medicare Supplementary Medical Insurance trust fund is automatically in financial balance, but policy makers remain concerned about continuing rapid cost increases. A new National Bipartisan Commission on the Future of Medicare will attempt to determine effective solutions to these long-range problems. [ABSTRACT FROM AUTHOR]
- Published
- 1998
9. Preoperative technetium Tc 99m sestamibi imaging. Paving the way to minimal-access parathyroid surgery.
- Author
-
Sofferman RA, Nathan MH, Fairbank JT, Foster RS Jr, and Krag DN
- Published
- 1996
10. SELECTIVE RENAL ARTERIOGRAPHY IN MEDICAL DISEASES OF THE KIDNEY
- Author
-
Shuford Wh, Foster Rs, and Weens Hs
- Subjects
Adult ,Male ,medicine.medical_specialty ,Occlusive disease ,Hydronephrosis ,Disease ,Renal arteriography ,Renal Artery ,Internal medicine ,medicine ,Humans ,Tuberculosis, Renal ,Radiology, Nuclear Medicine and imaging ,Polycystic Kidney Diseases ,Kidney ,Nephrosclerosis ,Pyelonephritis ,business.industry ,Angiography ,Renal vein thrombosis ,General Medicine ,Middle Aged ,medicine.disease ,Arterial occlusion ,Black or African American ,medicine.anatomical_structure ,Cardiology ,Female ,Kidney Diseases ,Radiology ,business ,Artery - Abstract
1. Selective renal arteriography permits visualization of the small intrarenal arteries to a degree approaching that obtained by opaque injection of anatomic specimens.2. The arteriographic features of benign and malignant hypertensive vascular disease, segmental arterial occlusion, pyelonephritis, hydronephrosis, tuberculosis, polycystic renal disease and unilateral renal vein thrombosis have been described.3. Emphasis has been placed on small vessel changes rather than main artery lesions in these disease entities. In some patients with occlusive disease of the main renal arteries, the status of the small intrarenal vessels may be of considerable importance.
- Published
- 1965
11. Neer total shoulder replacement in rheumatoid arthritis
- Author
-
Kelly, IG, Foster, RS, and Fisher, WD
- Abstract
Forty-two shoulders in 37 patients with polyarthritis were treated with Neer total shoulder replacements and reviewed 12 to 66 months afterwards. There was good pain relief and improvement in function, but the range of movement was less than that seen after replacements for osteoarthritis; this may have been related to the fact that 34 shoulders had abnormal rotator cuff tendons. Although there was a high incidence of radiolucent lines around the glenoid component, there was no clinical evidence of loosening. There were a few complications, but on the whole we feel that the Neer total shoulder arthroplasty is a valuable procedure for a patient with polyarthritis.
- Published
- 1987
- Full Text
- View/download PDF
12. Hypopigmented papules in a toddler.
- Author
-
FitzGerald HA, Mei A, Kim J, Ardakani NM, and Foster RS
- Subjects
- Child, Preschool, Humans, Diagnosis, Differential, Hypopigmentation pathology, Hypopigmentation diagnosis
- Published
- 2024
- Full Text
- View/download PDF
13. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
- Author
-
Burns MJ, Ponting DJ, Foster RS, Thornton BP, Romero NE, Smith GF, Ashworth IW, Teasdale A, Simon S, and Schlingemann J
- Subjects
- Humans, Amines chemistry, Pharmaceutical Preparations, Nitrosamines chemistry
- Abstract
N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of nitrosamines that can potentially be derived from small molecule drugs and their known impurities described in a previous publication, we have now re-analyzed this dataset to apply EMA's Carcinogenic Potency Categorization Approach (CPCA) introduced with the 16th revision of their Q&A document for Marketing Authorization Holders. We find that the majority of potential nitrosamines from secondary amine precursors belongs to potency categories 4 and 5, corresponding to an acceptable daily intake of 1500 ng, whereas nitrosamines from tertiary amine precursors distribute more evenly among all categories, resulting in a substantial number of structures that are assigned the more challenging acceptable intakes of 18 ng/day and 100 ng/day for potency categories 1 and 2, respectively. However, the nitrosative dealkylation pathway for tertiary amine is generally far slower than the direct nitrosation on secondary amines, with a direct nitrosation mechanism suspected only for structures featuring electron-rich (hetero)aromatic substituents. This allows for greater focus towards those structures that require further review, and we demonstrate that their number is not substantial. In addition, we reflect on the nitrosamine risk posed by secondary amine API impurities and demonstrate that based on the ICH Q3A/B identification threshold unknown impurities may exist that could be transformed to relevant amounts of NA. We also demonstrate that the analytical sensitivity required for the quantification of high potency nitrosamines can be problematic especially for high dose APIs. In summary, the regulatory framework rolled out with the latest Q&A document represents a substantial improvement compared with the previous situation, but further refinement through interaction between manufacturers, regulators, not-for-profit and academic institutions will be required to ensure patient access to vital medicines without compromising safety., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments.
- Author
-
Cayley AN, Foster RS, Brigo A, Muster W, Musso A, Kenyon MO, Parris P, White AT, Cohen-Ohana M, Nudelman R, and Glowienke S
- Abstract
Expert review of two predictions, made by complementary (quantitative) structure-activity relationship models, to an overall conclusion is a key component of using in silico tools to assess the mutagenic potential of impurities as part of the ICH M7 guideline. In lieu of a specified protocol, numerous publications have presented best practise guides, often indicating the occurrence of common prediction scenarios and the evidence required to resolve them. A semi-automated expert review tool has been implemented in Lhasa Limited's Nexus platform following collation of these common arguments and assignment to the associated prediction scenarios made by Derek Nexus and Sarah Nexus. Using datasets primarily donated by pharmaceutical companies, an automated analysis of the frequency these prediction scenarios occur, and the likelihood of the associated arguments assigning the correct resolution, could then be conducted. This article highlights that a relatively small number of common arguments may be used to accurately resolve many prediction scenarios to a single conclusion. The use of a standardised method of argumentation and assessment of evidence for a given impurity is proposed to improve the efficiency and consistency of expert review as part of an ICH M7 submission., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alex Cayley and Robert S. Foster are employees of Lhasa Limited, a non-profit organisation which produces, licenses, and maintains the (Q)SAR systems described as example implementations of this work., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. Diagnosis, assessment and management of atopic dermatitis in children with skin of colour.
- Author
-
Gan C, Brand R, Foster RS, Weidinger J, and Rodrigues M
- Subjects
- Humans, Child, Skin Pigmentation, Skin, Treatment Outcome, Dermatitis, Atopic diagnosis, Dermatitis, Atopic therapy, Dermatitis, Atopic etiology, Psoriasis complications
- Abstract
Background: It is important to be able to manage patients regardless of ethnicities. The understanding of skin diseases, including atopic dermatitis, in patients with skin of colour (SOC) is lagging compared with that in patients with lighter skin and has been identified as an educational gap among medical practitioners., Objective: This paper synthesises the latest literature on the diagnosis, assessment, treatment outcomes and cultural considerations for managing atopic dermatitis in children with SOC in the general practice setting., Discussion: Atopic dermatitis in children with SOC can vary from traditional descriptions and appear psoriasiform, lichenoid, scaly, papular, hypopigmented or violaceous. It can be misdiagnosed and its severity underestimated. Complications from atopic dermatitis, as well as the treatments provided, might result in inadequate treatment unless the treating doctor is aware of specific nuances in children with SOC.
- Published
- 2023
- Full Text
- View/download PDF
16. Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project.
- Author
-
Furuhama A, Kitazawa A, Yao J, Matos Dos Santos CE, Rathman J, Yang C, Ribeiro JV, Cross K, Myatt G, Raitano G, Benfenati E, Jeliazkova N, Saiakhov R, Chakravarti S, Foster RS, Bossa C, Battistelli CL, Benigni R, Sawada T, Wasada H, Hashimoto T, Wu M, Barzilay R, Daga PR, Clark RD, Mestres J, Montero A, Gregori-Puigjané E, Petkov P, Ivanova H, Mekenyan O, Matthews S, Guan D, Spicer J, Lui R, Uesawa Y, Kurosaki K, Matsuzaka Y, Sasaki S, Cronin MTD, Belfield SJ, Firman JW, Spînu N, Qiu M, Keca JM, Gini G, Li T, Tong W, Hong H, Liu Z, Igarashi Y, Yamada H, Sugiyama KI, and Honma M
- Subjects
- Mutagenicity Tests, Mutagenesis, Japan, Mutagens toxicity, Mutagens chemistry, Quantitative Structure-Activity Relationship
- Abstract
Quantitative structure-activity relationship (QSAR) models are powerful in silico tools for predicting the mutagenicity of unstable compounds, impurities and metabolites that are difficult to examine using the Ames test. Ideally, Ames/QSAR models for regulatory use should demonstrate high sensitivity, low false-negative rate and wide coverage of chemical space. To promote superior model development, the Division of Genetics and Mutagenesis, National Institute of Health Sciences, Japan (DGM/NIHS), conducted the Second Ames/QSAR International Challenge Project (2020-2022) as a successor to the First Project (2014-2017), with 21 teams from 11 countries participating. The DGM/NIHS provided a curated training dataset of approximately 12,000 chemicals and a trial dataset of approximately 1,600 chemicals, and each participating team predicted the Ames mutagenicity of each trial chemical using various Ames/QSAR models. The DGM/NIHS then provided the Ames test results for trial chemicals to assist in model improvement. Although overall model performance on the Second Project was not superior to that on the First, models from the eight teams participating in both projects achieved higher sensitivity than models from teams participating in only the Second Project. Thus, these evaluations have facilitated the development of QSAR models.
- Published
- 2023
- Full Text
- View/download PDF
17. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
- Author
-
Tachibana I, Alabd A, Whaley RD, McFadden J, Piroozi A, Hassoun R, Kern SQ, King J, Adra N, Rice KR, Foster RS, Einhorn LH, Cary C, and Masterson TA
- Subjects
- Male, Humans, Treatment Outcome, Lymph Node Excision, Retroperitoneal Space surgery, Retroperitoneal Space pathology, Retrospective Studies, Seminoma drug therapy, Seminoma surgery, Seminoma pathology, Neoplasms, Germ Cell and Embryonal surgery, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery, Testicular Neoplasms pathology
- Abstract
Purpose: Patients with relapsed seminoma after first-line chemotherapy can be treated with salvage chemotherapy or postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Based on prior experience, surgical management can have worse efficacy and increased morbidity compared to nonseminomatous germ cell tumor. Our aim was to characterize the surgical efficacy and difficulty in highly selected patients with residual disease after first-line chemotherapy., Materials and Methods: The Indiana University testis cancer database was queried to identify men who underwent PC-RPLND for seminoma between January 2011 and December 2021. Included patients underwent first-line chemotherapy and had evidence of retroperitoneal disease progression., Results: We identified 889 patients that underwent PC-RPLND, of which only 14 patients were operated on for seminoma. One patient was excluded for lack of follow-up. Out of 13 patients, only 3 patients were disease free with surgery only. Median follow up time was 29.9 months (interquartile ranges : 22.6-53.7). Two patients died of disease. The remaining 8 patients were treated successfully with salvage chemotherapy. During PC-RPLND, 4 patients required nephrectomy, 1 patient required an aortic graft, 2 patients required a partial ureterectomy, and 3 patients required partial or complete caval resection., Conclusion: The decision between salvage chemotherapy and PC-RPLND as second-line therapy can be challenging. Salvage chemotherapy is effective but is associated with short and long-term morbidity. Surgical efficacy in this setting seems to be limited, but careful selection of patients may lead to surgical success without affecting the ability to receive any systemic salvage therapies if necessary or causing life-threating morbidity., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?
- Author
-
Tachibana I, Alabd A, Tong Y, Piroozi A, Mahmoud M, Kern SQ, Masterson TA, Adra N, Foster RS, Hanna NH, Einhorn LH, and Cary C
- Subjects
- Humans, Male, Lymph Node Excision methods, Neoplasm Staging, Recurrence, Retroperitoneal Space pathology, Retroperitoneal Space surgery, Retrospective Studies, Treatment Outcome, Neoplasms, Germ Cell and Embryonal pathology, Seminoma surgery, Testicular Neoplasms surgery, Testicular Neoplasms drug therapy
- Abstract
Purpose: On the basis of National Comprehensive Cancer Network guidelines, clinical stage (CS) II seminoma is treated with radiotherapy or chemotherapy. Primary retroperitoneal lymph node dissection (RPLND) demonstrated recent success as first-line therapy for RP-only disease. Our aim was to confirm surgical efficacy and evaluate recurrences after primary RPLND for CS IIA/IIB seminoma to determine if various clinical factors could predict recurrences., Patients and Methods: Patients who underwent primary RPLND for seminoma from 2014 to 2021 were identified. All patients had at least 6 months of follow-up. Nineteen patients were part of a clinical trial. Patients receiving adjuvant chemotherapy were excluded from Kaplan-Meier recurrence-free survival (RFS) analysis., Results: We identified 67 patients who underwent RPLND for RP-only seminoma. One patient had pN0 disease. Median follow-up time after RPLND was 22.4 months (interquartile range, 12.3-36.1 months) and 11 patients were found to have a recurrence. The 2-year RFS for RPLND-only patients without adjuvant chemotherapy was 80.2%. Patients who developed RP disease for a period > 12 months had the lowest chance of recurrence, with a 2-year RFS of 92.2%. Seven initial CS II patients were on surveillance for 3-12 months before surgery and no patients experienced recurrence. Pathologic nodal stage and high-risk factors such as tumor size > 4 cm or rete testis invasion of the orchiectomy specimen did not affect recurrence., Conclusion: CS II seminoma can be treated with surgery to avoid rigors of chemotherapy or radiotherapy. Patients with delayed development of CS II disease (> 12 months) had the best surgical results. Patients may present with borderline CS II disease, and careful surveillance may avoid overtreatment. Further study on patient selection and extent of dissection remains uncertain and warrants further investigation.
- Published
- 2023
- Full Text
- View/download PDF
19. Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.
- Author
-
Richardson NH, Althouse SK, Ashkar R, Cary C, Masterson T, Foster RS, Einhorn LH, and Adra N
- Subjects
- Male, Humans, Neoplasm Recurrence, Local pathology, Chronic Disease, Retrospective Studies, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery, Testicular Neoplasms diagnosis, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal surgery, Seminoma drug therapy, Seminoma surgery
- Abstract
Background: Late relapse (LR) of germ cell tumor (GCT) is defined as relapsed disease >2 years from initial treatment. LR remains a challenge both for optimal screening methods and management. We report the method of detection, treatments received, and outcomes in patients with chemotherapy-exposed vs chemotherapy-naïve LR GCT., Patients and Methods: The Indiana University testicular cancer database was queried identifying 131 patients with LR GCT evaluated at Indiana University from January 2000 to January 2019. Method of detection of LR was recorded along with site, treatment received, and survival outcomes. The cohort was divided into 4 groups according to seminoma versus non-seminoma GCT (NSGCT) and chemotherapy-exposed vs chemotherapy-naïve LR. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and compared using the log-rank test. Medians with 95% confidence intervals were also calculated along with the 2-year probabilities., Results: Median age at LR was 38.3 (range, 19.3-56.8). Chemotherapy-exposed accounted for 75 (57%) and chemotherapy-naïve for 56 (43%) of cases. The 2-year OS comparing chemotherapy-exposed versus chemotherapy-naïve was 78.2% versus 100% (P = .0003). For the 72 chemo-exposed NSGCT LR pts, 2-year PFS based on treatment: surgery vs chemotherapy versus surgery + chemotherapy was 67.1% versus 0% versus 47.1% (P < 0.0001). Fifty-nine percent of chemotherapy-exposed LR had elevation of alpha fetoprotein (AFP) at LR diagnosis., Conclusion: GCT pts require lifetime follow-up with annual physical exam and tumor markers. Surgical resection, when feasible, remains the preferred treatment for chemotherapy-exposed LR. Chemotherapy-exposed LR has worse outcomes compared to chemotherapy-naïve LR patients., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
- Author
-
Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA, Adra N, Foster RS, Einhorn LH, and Cary C
- Subjects
- Male, Humans, Lymph Node Excision, Chemotherapy, Adjuvant, Neoplasms, Germ Cell and Embryonal surgery, Neoplasms, Germ Cell and Embryonal drug therapy, Testicular Neoplasms pathology
- Published
- 2023
- Full Text
- View/download PDF
21. Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment
- Author
-
Cayley AN, Foster RS, Hill E, Kane S, Kocks G, Myden A, Newman D, Stalford SA, Vessey JD, Zarei R, and De Oliveira AAF
- Subjects
- Humans, Mutagenicity Tests methods, Carcinogens toxicity, Employment, Risk Assessment, Adverse Outcome Pathways
- Abstract
The traditional paradigm for safety assessment of chemicals for their carcinogenic potential to humans relies heavily on a battery of well-established genotoxicity tests, usually followed up by long-term, high-dose rodent studies. There are a variety of problems with this approach, not least that the rodent may not always be the best model to predict toxicity in humans. Consequently, new approach methodologies (NAMs) are being developed to replace or enhance predictions coming from the existing assays. However, a combination of the data arising from NAMs is likely to be required to improve upon the current paradigm, and consequently a framework is needed to combine evidence in a meaningful way. Adverse outcome pathways (AOPs) represent an ideal construct on which to organize this evidence. In this work, a data structure outlined previously was used to capture AOPs and evidence relating to carcinogenicity. Knowledge held within the predictive system Derek Nexus was extracted, built upon, and arranged into a coherent network containing 37 AOPs. 60 assays and 351 in silico alerts were then associated with KEs in this network, and it was brought to life by associating data and contextualizing evidence and predictions for over 13,400 compounds. Initial investigations into using the network to view knowledge and reason between evidence in different ways were made. Organizing knowledge and evidence in this way provides a flexible framework on which to carry out more consistent and meaningful carcinogenicity safety assessments in many different contexts.
- Published
- 2023
- Full Text
- View/download PDF
22. Lipschütz ulceration in a 12-year-old girl following second dose of Comirnaty (Pfizer) COVID-19 vaccine.
- Author
-
Frederiks AJ, Foster RS, and Ricciardo B
- Abstract
Competing Interests: None.
- Published
- 2022
- Full Text
- View/download PDF
23. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
- Author
-
Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA, Adra N, Foster RS, Einhorn LH, and Cary C
- Subjects
- Male, Humans, Neoplasm Staging, Neoplasm Recurrence, Local pathology, Lymph Node Excision, Retroperitoneal Space pathology, Retroperitoneal Space surgery, Chemotherapy, Adjuvant, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal surgery, Neoplasms, Germ Cell and Embryonal pathology, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery, Testicular Neoplasms pathology
- Abstract
Purpose: According to National Comprehensive Cancer Network guidelines, adjuvant chemotherapy (AC) has been advocated after primary retroperitoneal lymph node dissection (RPLND) to reduce the risk of relapse in pathologic nodal (pN) stage pN2 or pN3, whereas surveillance is preferred for pN1. We sought to explore the oncologic efficacy of primary RPLND alone for pathologic stage II in nonseminomatous germ cell tumors (NSGCTs) to reduce overtreatment with chemotherapy., Methods: Patients with pathologic stage II NSGCT after primary RPLND between 2007 and 2017 were identified. Patients were excluded for elevated preoperative serum tumor markers, receipt of AC, or if pure teratoma or primitive neuroectodermal tumor elements were found in the retroperitoneal pathology., Results: We identified 117 patients with active NSGCT in the retroperitoneum after primary RPLND. We excluded seven patients who lacked meaningful follow-up and 13 patients who received AC. There were 97 patients treated with RPLND alone: 41 pN1, 46 pN2, and 10 pN3. In total, 77 of 97 patients had not recurred after a median follow-up time of 52 months. The 2-year recurrence-free survival (RFS) was 80.3%, and the 5-year RFS was 79%. No differences in RFS were noted among nodal stage-pN1, pN2, and pN3-on Kaplan-Meier analysis. Lymphovascular invasion in the orchiectomy specimen, a high-risk pathologic feature, was also predictive of recurrence after primary RPLND. All 20 patients who recurred were treated with first-line chemotherapy and remained continuously disease free., Conclusion: Most men with pathologic stage II disease treated with surgery alone in our series never experienced a recurrence. We did not observe a difference in recurrences between patients with pN1 and pN2. The recommendation for AC for pN2 disease may be overtreatment in most patients.
- Published
- 2022
- Full Text
- View/download PDF
24. Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
- Author
-
King JM, Althouse S, Cary C, Masterson T, Foster RS, Ashkar R, Hanna NH, Einhorn LH, and Adra N
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Male, Neoplasm Recurrence, Local drug therapy, Retrospective Studies, Neoplasms, Germ Cell and Embryonal drug therapy, Testicular Neoplasms pathology
- Abstract
Purpose: The optimal management of patients with metastatic germ cell tumors who achieve a complete response (CR) after first-line chemotherapy remains unsettled. This study reports long-term outcomes of patients with metastatic germ cell tumor managed with surveillance after achieving a CR to first-line chemotherapy., Materials and Methods: Patients with metastatic nonseminomatous germ cell tumor treated at Indiana University between 1990 and 2017 who achieved a CR after first-line chemotherapy and were monitored with surveillance were retrospectively analyzed. CR was defined as normalization of tumor markers AFP and hCG, and no residual mass >1 cm in long axis. Kaplan-Meier methods were used to analyze progression-free survival (PFS) and overall survival (OS)., Results: Three hundred sixty-seven patients achieved a CR and were managed with surveillance. After a median followup of 4.97 years, 34 patients had disease progression. At most recent followup, 346 (94%) patients were alive with no evidence of disease, 10 patients (2.7%) died of their disease, 5 (1.4%) died of other causes and 6 (1.6%) were lost to followup. The estimated 2-year PFS was 91% (95% CI: 87%-94%) and 2-year OS was 98% (95% CI: 96%-99%). The estimated 2-year PFS by International Germ Cell Cancer Collaborative Group risk category was 92% for good vs 90% for intermediate vs 87% for poor risk (p=0.15), and the estimated 2-year OS was 99% for good vs 96% for intermediate vs 93% for poor risk disease (p=0.001)., Conclusions: Patients with metastatic nonseminomatous germ cell tumor who achieve a CR after first-line chemotherapy can be observed. Most patients who relapse can be salvaged with surgery and/or chemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
25. Updating the Dermal Sensitisation Thresholds using an expanded dataset and an in silico expert system.
- Author
-
Chilton ML, Api AM, Foster RS, Gerberick GF, Lavelle M, Macmillan DS, Na M, O'Brien D, O'Leary-Steele C, Patel M, Ponting DJ, Roberts DW, Safford RJ, and Tennant RE
- Subjects
- Computer Simulation, Expert Systems, Humans, Local Lymph Node Assay, Risk Assessment, Skin, Dermatitis, Allergic Contact etiology, Skin Tests standards
- Abstract
The Dermal Sensitisation Thresholds (DST) are Thresholds of Toxicological Concern, which can be used to justify exposure-based waiving when conducting a skin sensitisation risk assessment. This study aimed to update the published DST values by expanding the size of the Local Lymph Node Assay dataset upon which they are based, whilst assigning chemical reactivity using an in silico expert system (Derek Nexus). The potency values within the expanded dataset fitted a similar gamma distribution to that observed for the original dataset. Derek Nexus was used to classify the sensitisation activity of the 1152 chemicals in the expanded dataset and to predict which chemicals belonged to a High Potency Category (HPC). This two-step classification led to three updated thresholds: a non-reactive DST of 710 μg/cm
2 (based on 79 sensitisers), a reactive (non-HPC) DST of 73 μg/cm2 (based on 331 sensitisers) and an HPC DST of 1.0 μg/cm2 (based on 146 sensitisers). Despite the dataset containing twice as many sensitisers, these values are similar to the previously published thresholds, highlighting their robustness and increasing confidence in their use. By classifying reactivity in silico the updated DSTs can be applied within a skin sensitisation risk assessment in a reproducible, scalable and accessible manner., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
26. Use of Lhasa Limited Products for the In Silico Prediction of Drug Toxicity.
- Author
-
Ponting DJ, Burns MJ, Foster RS, Hemingway R, Kocks G, MacMillan DS, Shannon-Little AL, Tennant RE, Tidmarsh JR, and Yeo DJ
- Subjects
- Animals, Computer Simulation, Drug-Related Side Effects and Adverse Reactions, Software
- Abstract
Lhasa Limited have had a role in the in silico prediction of drug and other chemical toxicity for over 30 years. This role has always been multifaceted, both as a provider of predictive software such as Derek Nexus, and as an honest broker for the sharing of proprietary chemical and toxicity data. A changing regulatory environment and the drive for the Replacement, Reduction and Refinement (the 3Rs) of animal testing have led both to increased acceptance of in silico predictions and a desire for the sharing of data to reduce duplicate testing. The combination of these factors has led to Lhasa Limited providing a suite of products and coordinating numerous data-sharing consortia that do indeed facilitate a significant reduction in the testing burden that companies would otherwise be laboring under. Many of these products and consortia can be organized into workflows for specific regulatory use cases, and it is these that will be used to frame the narrative in this chapter., (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
27. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
- Author
-
Calaway AC, Kern SQ, Crook D, Tong Y, Masterson TA, Adra N, Einhorn LH, Foster RS, and Cary C
- Subjects
- Adult, Combined Modality Therapy, Humans, Male, Neoplasms, Germ Cell and Embryonal drug therapy, Retrospective Studies, Risk Assessment, Testicular Neoplasms drug therapy, Young Adult, Lymph Node Excision, Neoplasms, Germ Cell and Embryonal surgery, Orchiectomy, Retroperitoneal Neoplasms epidemiology, Teratoma epidemiology, Testicular Neoplasms surgery
- Abstract
Purpose: Presence of teratoma in the orchiectomy and residual retroperitoneal mass size are known predictors of finding teratoma during postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We sought to determine if the percentage of teratoma in the orchiectomy specimen could better stratify the risk of teratoma in the retroperitoneum., Materials and Methods: The Indiana University Testis Cancer Database was reviewed to identify patients who underwent PC-RPLND for nonseminomatous germ cell tumors from 2010 to 2018. A logistic regression model was fit to predict the presence of retroperitoneal teratoma using teratoma and yolk sac tumor in the orchiectomy, residual mass size and log transformed values of prechemotherapy alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin. The study cohort was split into 60% training and 40% validation sets using 200 bootstraps. A predictive nomogram was developed for predicting teratoma in the retroperitoneum., Results: A total of 422 men were included. Presence of teratoma in the orchiectomy (OR 1.02, p <0.001), residual mass size (OR 1.16, p <0.001) and log transformed prechemotherapy AFP (OR 1.12, p=0.002) were predictive factors for having teratoma in the retroperitoneum. The C-statistic using this model demonstrated a predictive ability of 0.77. Training set C-statistic was 0.78 compared to 0.75 for the validation set. A nomogram was developed to aid in clinical utility., Conclusions: The model better predicts patients at higher risk for teratoma in the retroperitoneum following chemotherapy, which can aid in a more informed referral for surgical resection.
- Published
- 2021
- Full Text
- View/download PDF
28. Systematic review of sirolimus in dermatological conditions.
- Author
-
Swarbrick AW, Frederiks AJ, and Foster RS
- Subjects
- Humans, Immunosuppressive Agents therapeutic use, Sirolimus therapeutic use, Skin Diseases drug therapy
- Abstract
Sirolimus is a mammalian target of rapamycin inhibitor (mTORI) with anti-proliferative, antiangiogenic and immunosuppressive properties. While approved in Australia as an anti-rejection medication for renal transplant patients, there is mounting evidence regarding the utility of oral and topical sirolimus in treating a plethora of dermatological conditions or conditions with cutaneous manifestations. Our aim was to present an overview of the evidence for current usage and breadth of the application of sirolimus in dermatology. We carried out a systematic review of all the literature published up to 31 August 2019 on oral and topical sirolimus with respect to dermatological conditions or conditions otherwise relevant to dermatology. While 3368 papers were initially produced in our search, 238 papers met our inclusion criteria and were examined in our review. The conditions examined were categorised into genodermatoses (9 conditions), infection (1 condition), inflammatory/autoimmune (10 conditions), neoplasm (3 conditions) and vascular (17 conditions). We extracted data on first author, publication year, journal, characteristics of the study and study patients, condition, drug modalities, drug efficacy, side effects, blood level of mTORI, co-interventions and follow-up. While there is level 1 evidence for the efficacy of sirolimus in conditions such as tuberous sclerosis complex (TSC) and GVHD prophylaxis, for many other conditions, the evidence is limited to level 4 evidence. Regarding oral systemic therapy, dosing regimens varied with the most common for children 0.8mg/m
2 twice daily and for adults 1 mg twice daily. Doses were often adjusted to reach a typical trough level of between 5 and 15 ng/mL, though targets often varied. In the overall majority of cases, side effects were minimal or tolerable, including mucositis, cytopenias, lipid abnormalities and nausea/vomiting, and only a few cases had to stop due to adverse effects. Regarding topical therapy, concentration of formulations varied from 0.1% to 1% and were compounded into creams, ointments or gels and administered typically once or twice per day. The most common side effect was skin irritation. There were a number of limitations to our study. In particular, many of the published studies were case reports or case series with no comparator arm, leading to susceptibility of bias in conclusions drawn, in particular a high likelihood of publication bias. Given the heterogeneity amongst studies, comparisons or aggregation of results was difficult. There continues to be growing use of oral and topical sirolimus in dermatological conditions. It provides new therapeutic options to patients where previous therapies have either failed or are limited due to toxicity. However, further studies are warranted., (© 2021 The Australasian College of Dermatologists.)- Published
- 2021
- Full Text
- View/download PDF
29. Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers.
- Author
-
Masterson TA, Cary C, and Foster RS
- Subjects
- Humans, Male, Testicular Neoplasms pathology, Treatment Outcome, Biomedical Research methods, Congresses as Topic standards, Lymph Node Excision methods, Testicular Neoplasms surgery
- Abstract
The role of surgery in the locoregional management of many solid tumors has long been established. For testicular cancer, the incorporation of lymphadenectomy has played an important part in generating long-term survival outcomes in excess of 90% for germ cell tumor patients. In this review, we address several clinical scenarios in which lymphadenectomy at times is underutilized, and others ill advised., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Lessons learned from 40 years of managing chylous ascites following RPLND.
- Author
-
Masterson TA, Cary C, and Foster RS
- Published
- 2021
- Full Text
- View/download PDF
31. Management of Metastatic Pure Teratoma in Chemotherapy Naive Patients With Testicular Primaries.
- Author
-
Cary C, Kern SQ, Jacob JM, Calaway AC, Foster RS, and Einhorn LH
- Subjects
- Adolescent, Adult, Humans, Male, Neoplasm Recurrence, Local epidemiology, Treatment Outcome, Young Adult, Lymph Node Excision methods, Teratoma surgery, Testicular Neoplasms surgery
- Abstract
Introduction: Patients diagnosed with stage II nonseminomatous germ cell tumors (NSGCT) often receive chemotherapy as primary treatment which exposes patients to immediate and long-term risks of chemotherapy. These risks can be avoided by proceeding to primary retroperitoneal lymph node dissection (RPLND) when a high suspicion of pure metastatic teratoma in the retroperitoneum (RP) exists. We propose that all stage II NSGCT patients with pure testicular teratoma, normal serum tumor markers, and with RP cystic metastases on imaging can safely be treated with primary RPLND., Methods: We identified 14 patients found to have 100% teratoma in orchiectomy specimens, negative serum tumor markers, and with metastatic cystic RP disease. Disease recurrence was also evaluated to establish efficacy of treatment., Results: All 14 patients were chemotherapy naive and found to have pure metastatic teratoma. All patients were IGCCCG good risk with stage IIA (21.4%), IIB (35.7%), and IIC (42.9%) disease. Median RP mass size was 4.9 cm (1.8 to 24 cm). All patients underwent a RPLND finding 100% teratoma in the RP. Median follow-up was 6.9 years. One patient (7.1%) who received a right modified template RPLND relapsed in the left RP 10.2 years later who underwent treatment and has been disease free for over 5.5 years., Conclusions: Primary surgical treatment in this cohort of pure metastatic teratoma resulted in good clinical outcomes and the ability to avoid unnecessary induction chemotherapy. It is important that contrary to previous suppositions, patients with pure teratoma of the testis can independently metastasize with teratoma only, without metastatic carcinoma.
- Published
- 2020
- Full Text
- View/download PDF
32. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7.
- Author
-
Foster RS, Fowkes A, Cayley A, Thresher A, Werner AD, Barber CG, Kocks G, Tennant RE, Williams RV, Kane S, and Stalford SA
- Abstract
The use of in silico predictions for the assessment of bacterial mutagenicity under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M7 guideline is recommended when two complementary (quantitative) structure-activity relationship (Q)SAR models are used. Using two systems may increase the sensitivity and accuracy of predictions but also increases the need to review predictions, particularly in situations where results disagree. During the 4th ICH M7/QSAR Workshop held during the Joint Meeting of the 6th Asian Congress on Environmental Mutagens (ACEM) and the 48th Annual Meeting of the Japanese Environmental Mutagen Society (JEMS) 2019, speakers demonstrated their approaches to expert review using 20 compounds provided ahead of the workshop that were expected to yield ambiguous (Q)SAR results. Dr. Chris Barber presented a selection of the reviews carried out using Derek Nexus and Sarah Nexus provided by Lhasa Limited. On review of these compounds, common situations were recognised and are discussed in this paper along with standardised arguments that may be used for such scenarios in future., Competing Interests: Competing interestsNot applicable., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
33. Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma.
- Author
-
Barboza MP, Speir RW, Boris RS, Calaway AC, Cary C, Foster RS, and Masterson TA
- Subjects
- Aged, Carcinoma, Renal Cell pathology, Female, Humans, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Retroperitoneal Space, Retrospective Studies, Salvage Therapy, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Lymph Node Excision, Lymphatic Metastasis, Neoplasm Recurrence, Local surgery, Nephrectomy
- Abstract
Purpose: To investigate oncological outcomes and relapse patterns in retroperitoneal lymph node (LN)-only recurrences with salvage retroperitoneal lymph node dissection (S-RPLND)., Materials and Methods: We reviewed records of 19 patients undergoing RPLND for RCC recurrences between 2011 and 2018. All patients initially had primary non-metastatic RCC, with subsequent recurrence restricted to the retroperitoneal lymph nodes (LN). LN recurrence sites after nephrectomy and relapses after S-RPLND were assessed. The primary outcomes were post-RPLND Relapse-Free Survival (RFS), and Cancer-Specific Survival (CSS)., Results: The median age of our cohort was 60 years at RPLND. Right and left nephrectomies were performed in 14 (73.7%) and 5 (26.3%), respectively. Clear cell carcinoma was found in 10 (52.6%) patients, followed by papillary in 4(21.1%), chromophobe in 2(10.5%), and 'other' in 3 (15.8%). The extent of lymphadenectomy during nephrectomy and S-RPLND varied based on surgical approach. The median follow-up time after S-RPLND of the entire cohort was 31.53 months, and the median RFS was 9.63 months. Overall, 4 patients died of cancer, of which 3 (75%) were N1 at time of nephrectomy. The CSS after RPLND at 3 and 5 years was 81.5% and 61.1%, respectively. The RFS after RPLND at 2 and 5 years was 44.4% and 29.6%, respectively., Conclusions: Our results suggest that aggressive surgical management provides satisfactory CSS with acceptable complication rates. Moreover, we believe this subset of patients with node-only recurrence showed an unpredictable pattern of lymphatic spread, with predilection for regional dissemination warranting surgical resection of LN recurrences in a bilateral template fashion when feasible., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
34. Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institution.
- Author
-
Abedali ZA, Monn MF, Huddleston P, Cleveland BE, Sulek J, Bahler CD, Foster RS, Koch MO, Mellon MJ, Kaimakliotis HZ, Cary C, Bihrle R, Gardner TA, Masterson TA, Boris RS, and Sundaram CP
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Postoperative Complications epidemiology, Retrospective Studies, Treatment Outcome, Kidney Neoplasms surgery, Nephrectomy methods, Robotic Surgical Procedures
- Abstract
Objective: To compare peri-operative factors and renal function following open partial nephrectomy (OPN) and robotic partial nephrectomy (RPN) for intermediate and high complexity tumors when controlling for tumor and patient complexity. Methods: A retrospective review of 222 patients undergoing partial nephrectomy was performed. Patients with intermediate (nephrometry score NS 7-9) or high (NS 10-12) complexity tumors were matched 2:1 for RPN:OPN using NS, Charlson Comorbidity Index (CCI), and BMI. Patient demographics, peri-operative values, renal function, and complication rates were analyzed and compared. Results: Seventy-four OPN patients were matched to 148 RPN patients with no difference in patient demographics. Estimated blood loss in OPN patients was significantly higher (368.5 vs 210.5 mL, p < 0.001) as was transfusion rate (17% vs 1.6%, p < 0.001). Warm ischemia time was longer in OPN (25.5 vs 19.7 min, p = 0.001) while operative time was reduced (200.5 vs 226.5 min, p = 0.010). RPN patients had significantly shorter hospitalizations (5.3 vs 3.0 days, p < 0.001). GFR decrease after one month was not statistically significant (12.9 vs 6.6 ml/min, p = 0.130). Clavien III-V complications incidence was higher for OPN compared to RPN although not significantly (20.3% vs 10.8%, p = 0.055). Conclusion: When matching for tumor and patient complexity, RPN patients had fewer high grade post-operative complications, decreased blood loss, and shorter hospitalizations. RPN is a safe option for patients with intermediate and high complexity tumors.
- Published
- 2020
- Full Text
- View/download PDF
35. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
- Author
-
Speir RW, Calaway AC, Einhorn LH, Foster RS, and Cary C
- Subjects
- Combined Modality Therapy, Humans, Lymphatic Metastasis, Male, Neoplasms, Germ Cell and Embryonal pathology, Retroperitoneal Space, Retrospective Studies, Testicular Neoplasms pathology, Chorionic Gonadotropin blood, Lymph Node Excision, Neoplasms, Germ Cell and Embryonal blood, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal surgery, Testicular Neoplasms blood, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery
- Abstract
Purpose: Choriocarcinoma germ cell tumors are rare and usually present with significantly elevated human chorionic gonadotropin (hCG) levels. When curable, it is felt to be largely a result of chemotherapy. We sought to determine the histologic characteristics for those undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) and compare them with metastatic nonseminomatous germ cell tumor (NSGCT) patients with similarly elevated hCG levels., Methods: We reviewed medical records of men undergoing PC-RPLND between 1988 and 2017 with postorchiectomy, preinduction chemotherapy hCG levels greater than 50,000 mIU/ml. They were stratified by primary tumor histology: Pure choriocarcinoma and mixed NSGCT. Clinical, pathologic, and serologic data were reported and logistic regression was used to assess for predictors of necrosis in the PC-RPLND specimen., Results: Our cohort consisted of 108 men. The mixed group (n = 91) had a median hCG of 165,177 mIU/ml, a postchemotherapy node size of 4.7 cm, of whom 19.8% also received salvage chemotherapy prior to RPLND. The pure choriocarcinoma group (n = 17) had a median hCG of 170,267 mIU/ml, a node size of 5.1 cm, of whom 17.6% received salvage chemotherapy. 88.2% of patients with choriocarcinoma had necrosis in the PC-RPLND specimen compared with 29.7% of the mixed NSGCT group (P = <0.0001). Controlling for salvage chemotherapy use, prechemotherapy hCG, node size and marker status, choriocarcinoma patients were 20 fold more likely to have necrosis on RPLND specimen (Odds ratio 20.68 [95% confidence interval 5.279-81.114])., Conclusion: While PC-RPLND is appropriate in patients with residual masses after chemotherapy, patients with pure choriocarcinoma presenting with significantly elevated hCG levels represent a unique patient population where necrosis is found more often than anticipated., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
36. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
- Author
-
Taza F, Chovanec M, Snavely A, Hanna NH, Cary C, Masterson TA, Foster RS, Einhorn LH, Albany C, and Adra N
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin administration & dosage, Cisplatin administration & dosage, Etoposide administration & dosage, Humans, Lymph Node Excision, Lymph Nodes surgery, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Metastasis, Orchiectomy, Prognosis, Progression-Free Survival, Retroperitoneal Space, Teratoma mortality, Teratoma surgery, Testicular Neoplasms mortality, Testicular Neoplasms surgery, Young Adult, Lymph Nodes pathology, Teratoma drug therapy, Teratoma pathology, Testicular Neoplasms drug therapy, Testicular Neoplasms pathology
- Abstract
Purpose: Presence of teratoma in patients with metastatic testicular germ cell tumor (GCT) is of unknown prognostic significance. We report survival outcomes of patients with or without teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen and assess impact on prognosis., Patients and Methods: Patients with metastatic nonseminomatous GCT (NSGCT) who were evaluated at Indiana University between 1990 and 2016 and had primary testicular tumor specimen from orchiectomy (ORCH) were included. All patients were treated with cisplatin-based combination chemotherapy. The cohort was divided into 2 groups according to presence or absence of teratoma in ORCH specimen. Survival data were correlated with histopathologic findings. Differences in progression-free (PFS) and overall survival (OS) were evaluated using log-rank tests and Cox proportional hazards models to adjust for known adverse prognostic factors., Results: We identified 1,224 consecutive patients evaluated at Indiana University between 1990 and 2016 who met inclusion criteria. Median age was 27 years (range, 13-71 years); 689 patients had teratoma in ORCH specimen, and 535 did not. With median follow-up of 2.3 years, 5-year PFS was 61.9% (95% CI, 57.1% to 66.2%) for those with teratoma versus 63.1% (95% CI, 58.0% to 67.8%) for those without ( P = .66); 5-year OS was 82.2% (95% CI, 77.9% to 85.8%) versus 81.4% (95% CI, 76.5% to 85.3%; P = .91), respectively. A total of 473 patients underwent PC-RPLND; 5-year PFS for patients with pure teratoma in PC-RPLND specimen versus necrosis only was 65.9% versus 79.1% ( P = .06), and 5-year OS was 90.3% versus 93.4% ( P = .21), respectively., Conclusion: Presence of teratoma in ORCH and PC-RPLND specimens was not a prognostic factor in this large retrospective study of patients with NSGCT.
- Published
- 2020
- Full Text
- View/download PDF
37. Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?
- Author
-
Calaway AC, Foster RS, Tong Y, Masterson TA, Bihrle R, and Cary C
- Subjects
- Acetaminophen pharmacology, Adult, Antineoplastic Combined Chemotherapy Protocols pharmacology, Gabapentin pharmacology, Humans, Male, Piperidines pharmacology, Postoperative Period, Retrospective Studies, Treatment Outcome, Acetaminophen therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gabapentin therapeutic use, Lymph Node Excision methods, Lymphatic Metastasis pathology, Neoplasms, Germ Cell and Embryonal drug therapy, Piperidines therapeutic use, Quality of Health Care standards, Testicular Neoplasms drug therapy
- Abstract
Introduction: To determine the benefits of alvimopan and multimodal pain management strategies in men undergoing retroperitoneal lymph node dissection for testicular cancer., Methods: A retrospective cohort study was completed in men undergoing retroperitoneal lymph node dissection from January 2017 to May 2018. Patients were placed into the 3-drug, 2-drug, and control cohorts as a result of a prospectively determined protocol during the study period. Men in the 3-drug group were managed using alvimopan 12 mg PO the morning of surgery then BID until bowel movement, gabapentin 300 mg daily, and acetaminophen 1,000 mg q6H. The 2-drug group was managed with the above regimen excluding alvimopan. Controls were treated per our standard perioperative pathway. Primary outcomes were length of stay, IV narcotic consumption, bowel movement during hospitalization, and time to bowel movement and assessed in multivariate models controlling for operative time, concomitant surgery, chemotherapy receipt, and residual mass size., Results: One-hundred and fifty-two consecutive patients underwent RPLND (42 3-drug, 38 2-drug, and 72 controls). Multivariable models indicated that the 3-drug (IRR 0.89, P < 0.0001) and 2-drug group (IRR 0.87, P = 0.0209) had shorter hospital stays than controls. Men in the 3-drug group required less narcotic pain medication than the 2-drug (β -8.16, P = 0.0405) and the control (β -8.16, P = 0.0302) group. Men receiving alvimopan (3-drug) were almost 6 times more likely than the 2-drug group (odds ratio 5.94, P < 0.0001) and 4 times more likely than the control group (odds ratio 3.86, P = 0.0017) to have a bowel movement during hospitalization. Men in the 3-drug group had the quickest return of bowel movements., Conclusions: Multimodal pain management improves length of stay in men undergoing retroperitoneal lymph node dissection for testis cancer. The addition of alvimopan allows for quicker return of bowel movements and reduces overall narcotic requirements., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
38. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer.
- Author
-
Calaway AC, Einhorn LH, Masterson TA, Foster RS, and Cary C
- Subjects
- Adult, Cost of Illness, Humans, Male, Middle Aged, Neoplasm Staging, Outcome and Process Assessment, Health Care, Retroperitoneal Space, Lymph Node Excision adverse effects, Lymph Node Excision instrumentation, Lymph Node Excision methods, Lymph Nodes pathology, Lymph Nodes surgery, Neoplasm Metastasis pathology, Neoplasm Metastasis therapy, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Neoplasms, Germ Cell and Embryonal pathology, Neoplasms, Germ Cell and Embryonal surgery, Postoperative Complications pathology, Postoperative Complications therapy, Robotic Surgical Procedures adverse effects, Robotic Surgical Procedures methods, Testicular Neoplasms pathology, Testicular Neoplasms surgery
- Abstract
Surgery for metastatic testicular disease has been an essential factor in the long-term cure rates for men with testicular germ cell tumors. Robotic approaches to retroperitoneal lymph node dissection (R-RPLND) have been proposed as an alternative to open surgery with few if any adverse events reported. We report the clinical course for five recent patients referred to our center for recurrences after R-RPLND, focusing on recurrence patterns, treatment burden, and treatment-related morbidity and mortality. The median time to recurrence after R-RPLND was 259d. The recurrence patterns after R-RPLND were aberrant from our past experience in managing recurrences after open RPLND. One man experienced an in-field recurrence located in close proximitry to an undivided lumbar vessel. Four patients had out-of-field recurrence in abnormal locations: pericolic space invading the sigmoid colon, peritoneal carcinomatosis with a perinephric mass, large-volume liver lesions with suprahilar disease extending into the retrocrural space, and lymph nodes in the celiac axis. The treatment burden was high: the five men were subjected to 12 different chemotherapy regimens and three underwent additional surgeries. Three patients developed significant cisplatin-induced toxicity. One patient died due to progression of testicular cancer after failing all chemotherapy and surgical options. PATIENT SUMMARY: We report our initial experience in managing patients with testicular cancer referred to our institution after robotic retroperitoneal lymph node dissection (RPLND). We found that the recurrences were highly variable and in unusual locations and were associated with a high treatment burden. We conclude that further investigation into the safety and long-term oncologic efficacy of robotic RPLND is necessary before widespread implementation., (Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Reply to Gregory J. Nason, Michael A.S. Jewett, and Robert J. Hamilton's Letter to the Editor re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-609: Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer.
- Author
-
Calaway AC, Einhorn LH, Masterson TA, Foster RS, and Cary C
- Subjects
- Humans, Lymph Node Excision, Male, Treatment Outcome, Neoplasms, Germ Cell and Embryonal, Robotic Surgical Procedures, Robotics, Testicular Neoplasms surgery
- Published
- 2019
- Full Text
- View/download PDF
40. Complications of Retroperitoneal Lymph Node Dissection.
- Author
-
Cary C, Foster RS, and Masterson TA
- Subjects
- Humans, Male, Recovery of Function, Lymph Node Excision, Lymphatic Metastasis pathology, Neoplasms, Germ Cell and Embryonal pathology, Postoperative Complications, Retroperitoneal Space pathology, Testicular Neoplasms pathology
- Abstract
Retroperitoneal lymph node dissection is an integral part of the management of testicular cancer. Surgical approach and outcomes have improved over the past decades. Several factors influence the complexity of the operation, including numerous patient characteristics and disease-related characteristics. An important consideration lies in the fact that this is largely a vascular operation, and techniques of vascular control should be comfortable for the urologic surgeon performing the procedure. This article discusses the known surgical complications related to this operation and their relative incidence reported throughout the literature., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors.
- Author
-
Calaway AC, Tachibana I, Masterson TA, Foster RS, Einhorn LH, and Cary C
- Subjects
- Adult, Cohort Studies, Databases, Factual, Disease-Free Survival, Hospitals, University, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Recurrence, Local mortality, Neoplasm Staging, Orchiectomy methods, Prognosis, Retroperitoneal Space, Retrospective Studies, Risk Assessment, Sex Cord-Gonadal Stromal Tumors pathology, Survival Analysis, Testicular Neoplasms pathology, Young Adult, Lymph Node Excision methods, Neoplasm Recurrence, Local pathology, Sex Cord-Gonadal Stromal Tumors mortality, Sex Cord-Gonadal Stromal Tumors surgery, Testicular Neoplasms mortality, Testicular Neoplasms surgery
- Abstract
Objective: To investigate the clinical history of patients with clinical stage II sex cord stromal tumors who underwent retroperitoneal lymph node dissection (RPLND) at our institution., Methods: Our prospectively maintained testicular cancer database was queried to identify patients who presented with or developed clinical stage II sex cord stromal tumors and underwent RPLND at our institution between 1980 and 2018. Demographic, clinical, and pathologic characteristics were reviewed. Kaplan-Meier curves were graphed to assess recurrence-free and overall survival., Results: Fourteen patients were included in the study with a median age of 44.2years. Four patients presented with clinical stage II disease and 10 patients developed metastatic disease during follow-up of initial clinical stage I disease with a median time to metastasis of 2.7years (range: 0.4-19.5 years). Of the 10 patients with orchiectomy pathology data available, all patients had at least 1 risk factor on testis pathology (mean: 2.9 risk factors). Nine patients received treatment prior to referral to our institution. All patients recurred post-RPLND at Indiana University. Median recurrence-free survival was 9.8 months. Twelve patients died of disease with a median overall survival of 14.4 months., Conclusion: Metastatic sex cord stromal tumors are rare and are more resistant to standard treatment modalities than metastatic germ cell tumors. Patients presenting with sex cord stromal tumors should consider prophylactic primary RPLND in the setting of 1 or more pathologic predictor of malignancy., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors.
- Author
-
Calaway AC, Foster RS, Adra N, Masterson TA, Albany C, Hanna NH, Einhorn LH, and Cary C
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin administration & dosage, Cisplatin administration & dosage, Etoposide administration & dosage, Humans, Length of Stay statistics & numerical data, Lung drug effects, Male, Neoplasms, Germ Cell and Embryonal surgery, Operative Time, Postoperative Hemorrhage, Retroperitoneal Space, Testicular Neoplasms surgery, Young Adult, Antibiotics, Antineoplastic adverse effects, Bleomycin adverse effects, Lymph Node Excision methods, Neoplasms, Germ Cell and Embryonal drug therapy, Testicular Neoplasms drug therapy
- Abstract
Purpose: Three cycles of bleomycin, etoposide, and cisplatin (BEP × 3) or four cycles of etoposide and cisplatin (EP × 4) are first-line chemotherapy regimens for men with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk germ cell tumors (GCTs). We determined whether inclusion of bleomycin affected pulmonary and operative morbidity after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND)., Patients and Methods: We queried our database to identify IGCCCG good-risk patients who received BEP × 3 or EP × 4 induction chemotherapy before PC-RPLND from 2006 to 2016. Patients who received combination regimens were excluded. The primary outcomes of interest were pulmonary morbidity (prolonged intubation, reintubation, supplemental oxygen use, intensive care unit stay) and operative morbidity (operative time, length of stay, concomitant procedures, estimated blood loss)., Results: We analyzed 234 patients (191 BEP × 3 v 43 EP × 4). All patients were extubated immediately after the operation. None were reintubated or discharged on oxygen. Two patients in each cohort required an intensive care unit stay for nonpulmonary reasons. Patients treated with BEP required shorter use of supplemental oxygen (0.99 v 1.63 days; P = .005). No significant differences were found in preoperative mass size ( P = .42) or concomitant surgeries ( P = .58). Operative time was significantly shorter (131 v 170 minutes; P < .01), and estimated blood loss was considerably less (194 v 226 mL; P < .01) in patients treated with BEP. Length of stay was shorter in patients treated with BEP (3.3 v 3.9 days; P < .01)., Conclusion: In a modern surgical cohort, the inclusion of bleomycin does not seem to influence pulmonary morbidity, operative difficulty, or nonpulmonary postoperative complications after PC-RPLND in men with IGCCCG good-risk GST.
- Published
- 2018
- Full Text
- View/download PDF
43. Management of patients with metastatic teratoma with malignant somatic transformation.
- Author
-
Speir R, Cary C, Foster RS, and Masterson TA
- Subjects
- Adenocarcinoma secondary, Chemotherapy, Adjuvant, Humans, Lymph Node Excision, Male, Metastasectomy, Neoplasm Recurrence, Local, Neuroectodermal Tumors, Primitive, Peripheral secondary, Prognosis, Retroperitoneal Space, Rhabdomyosarcoma secondary, Sarcoma therapy, Teratoma secondary, Testicular Neoplasms pathology, Adenocarcinoma therapy, Cell Transformation, Neoplastic, Neuroectodermal Tumors, Primitive, Peripheral therapy, Rhabdomyosarcoma therapy, Teratoma therapy, Testicular Neoplasms therapy
- Abstract
Purpose of Review: The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST)., Recent Findings: The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse., Summary: Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.
- Published
- 2018
- Full Text
- View/download PDF
44. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
- Author
-
Cary C, Jacob JM, Albany C, Masterson TA, Hanna NH, Einhorn LH, and Foster RS
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin therapeutic use, Cisplatin therapeutic use, Drug Administration Schedule, Etoposide therapeutic use, Humans, Induction Chemotherapy, Male, Middle Aged, Survival Analysis, Treatment Outcome, Young Adult, Bleomycin administration & dosage, Cisplatin administration & dosage, Etoposide administration & dosage, Lymph Node Excision methods, Neoplasms, Germ Cell and Embryonal therapy, Testicular Neoplasms therapy
- Abstract
Background: Patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk testicular cancer might receive either 4 cycles of etoposide and cisplatin (EP × 4) or 3 cycles of bleomycin, etoposide, and cisplatin (BEP × 3). We sought to examine differences in survival after retroperitoneal lymph node dissection (PC-RPLND) between patients who received EP × 4 compared with BEP × 3., Patients and Methods: The Indiana University Testis Cancer database was queried to identify IGCCCG good-risk PC-RPLND patients who received either EP × 4 or BEP × 3 induction chemotherapy. The primary outcome was overall survival (OS). Kaplan-Meier plots were generated for the EP × 4 and BEP × 3 groups and compared using the log rank test. Cox regression analysis was used to determine risk of mortality., Results: A total of 223 patients met inclusion criteria between 1985 and 2011. Induction chemotherapy consisted of EP × 4 in 45 (20%) patients and BEP × 3 in 178 (80%). Most patients (78%) received their chemotherapy at outside institutions and were subsequently referred for PC-RPLND. The location of treating institution did not influence outcomes significantly when similar chemotherapy regimens were compared in this good-risk cohort. The 10-year OS for the EP × 4 and BEP × 3 groups were 91% and 98%, respectively (log rank P < .01). The adjusted risk of death in the EP × 4 group showed a nonsignificant trend of 3 times greater compared with the BEP × 3 group (hazard ratio, 3.1; 95% confidence interval, 0.8-12.0; P = .10)., Conclusion: The regimen of BEP × 3 resulted in a trend toward improved survival, however, this did not reach statistical significance. The location of treating institution seems less important in this risk group of patients., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
45. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
- Author
-
Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, Kesler K, Ulbright TM, Cheng L, Chovanec M, Taza F, Ku K, Brames MJ, Hanna NH, and Einhorn LH
- Subjects
- Adolescent, Adult, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local surgery, Progression-Free Survival, Retrospective Studies, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Medical Oncology methods, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal mortality
- Abstract
Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program., Patients and Methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n = 622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS., Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value <0.0001., Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort., (© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
46. Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens.
- Author
-
Harari SE, Sassoon DJ, Priemer DS, Jacob JM, Eble JN, Caliò A, Grignon DJ, Idrees M, Albany C, Masterson TA, Hanna NH, Foster RS, Ulbright TM, Einhorn LH, and Cheng L
- Subjects
- Adolescent, Adult, Aged, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal pathology, Testicular Neoplasms pathology, Young Adult, Neoplasms, Germ Cell and Embryonal diagnosis, Neoplasms, Germ Cell and Embryonal surgery, Orchiectomy methods, Testicular Neoplasms diagnosis, Testicular Neoplasms surgery
- Abstract
Background: Radical orchiectomy specimens present a unique set of challenges for pathology assessment owing to their rarity and complexity. This study compares second opinion pathology reports generated at a single, large academic institution to primary reports from outside hospitals., Methods: A database search was conducted for orchiectomy cases that were sent to our institution for management of testicular cancer from 2014 to 2015. Cases sent for consultation without a finalized diagnosis from the outside hospitals were excluded. A total of 221 consecutive cases were evaluated for comparison of final diagnoses between the outside institution and central pathology review., Results: This study revealed significant discrepancy involving multiple parameters between original and second opinion pathology reports. Of 221 cases of germ cell tumors assessed, 31% showed some discrepancy of histologic subtype. Overall, reporting of lymphovascular invasion changed in 22% of cases; of those, initially called positive 23% were changed to negative and of those initially called negative 12% were changed to positive. Although the overall discrepancy for spermatic cord invasion was 9%, an initial positive diagnosis was negated 35% of the time. The pathologic stage was altered in 23% of cases, mostly secondary to differences interpreting lymphovascular and spermatic cord invasion., Conclusion: Pathologists evaluating orchiectomy specimens should be aware of the major pitfalls in classification and staging, many of which may affect patient management., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
47. Granular parakeratosis induced by benzalkonium chloride exposure from laundry rinse aids.
- Author
-
Robinson AJ, Foster RS, Halbert AR, King E, and Orchard D
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Laundering, Male, Benzalkonium Compounds adverse effects, Household Products adverse effects, Parakeratosis chemically induced, Parakeratosis pathology
- Abstract
Benzalkonium chloride is a quaternary ammonium cationic detergent present in a number of household products, which can act as a major skin irritant. We present the case of six children who developed granular parakeratosis after exposure to benzalkonium chloride in laundry rinse aids, presenting as a brightly erythematous, tender but minimally pruritic, intertriginous eruption followed by superficial desquamation. The eruptions resolved over 3-4 weeks after cessation of exposure., (© 2016 The Australasian College of Dermatologists.)
- Published
- 2017
- Full Text
- View/download PDF
48. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.
- Author
-
Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihrle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck SDW, Grignon DJ, Cheng L, Albany C, and Hahn NM
- Subjects
- Aged, Carcinoma in Situ pathology, Carcinoma in Situ surgery, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell surgery, Cystectomy, Disease-Free Survival, Drug Therapy, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Invasiveness, Odds Ratio, Prognosis, Retrospective Studies, Treatment Outcome, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery, Antineoplastic Agents therapeutic use, Carcinoma in Situ drug therapy, Carcinoma, Transitional Cell drug therapy, Cisplatin therapeutic use, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes., Materials and Methods: Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were compared. The secondary analyses included tumor response, progression-free survival (PFS), overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only (pTisN0) at cystectomy., Results: A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of the patients. The absence of TURBT CIS was associated with a significantly increased pCR rate (23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, 1.19-13.98; P = .025). Stage pTisN0 disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not significantly affect the PFS or OS outcomes. Post hoc analysis of the pTisN0 patients revealed prolonged median PFS (104.5 vs. 139.9 months; P = .055) and OS (104.5 vs. 152.3 months; P = .091) outcomes similar to those for the pCR patients., Conclusion: The absence of CIS on pretreatment TURBT in patients with MIUC undergoing NAC was associated with increased pCR rates, with no observed differences in PFS or OS. Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to those for pCR patients. Further studies aimed at understanding the biology and clinical effect of CIS in MIUC are warranted., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
49. Preoperative Nomograms for Predicting Renal Function at 1 Year After Partial Nephrectomy.
- Author
-
Shum CF, Bahler CD, Cary C, Masterson TA, Boris RS, Gardner TA, Kaimakliotis HZ, Foster RS, Bihrle R, Koch MO, Slaven JE Jr, and Sundaram CP
- Subjects
- Aged, Female, Glomerular Filtration Rate physiology, Humans, Hypertension physiopathology, Kidney Neoplasms complications, Linear Models, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Kidney Neoplasms surgery, Nephrectomy methods, Nomograms, Renal Insufficiency, Chronic physiopathology
- Abstract
Introduction: Partial nephrectomy (PN) reduces the risk of postoperative chronic renal insufficiency (CRI). However, some patients still develop CRI after PN, and may eventually require dialysis. Being able to predict renal function before PN helps in counseling patients and managing expectations. We aimed to construct nomograms that predict estimated glomerular filtration rates (eGFRs), defined by the modification of diet in renal disease (MDRD) and the chronic kidney disease epidemiology collaboration (CKD-EPI) formulae, at 1 year after PN, using only preoperative covariates as predictors., Patients and Methods: We identified patients who underwent PN in our institution between 2004 and 2016, with known postoperative serum creatinine levels at 1 year. The preoperative covariates included patients' demographics, chronic comorbid conditions, tumor characteristics, and preoperative renal status. The endpoints were eGFRs at 1 year after PN, calculated using the MDRD and the CKD-EPI formulae. We first identified preoperative covariates with significant associations with the endpoints by Pearson correlation and independent samples t-test. Suitable covariates were then included in two multivariate linear regression models, for constructing and internally validating two nomograms., Results: 461 patients were eligible for analysis. The percentage of patients with eGFR below 60 mL/min/1.73 m
2 increased from 25% before PN to 35% at 1 year after PN. We included age, gender, African American race, body mass index, preoperative creatinine level, ipsilateral renal volume, solitary kidney status, tumor diameter, hypertension, diabetes, ischemic heart disease, and previous stroke in the multivariate linear regression models for nomogram construction. Internal validation showed bootstrap-corrected coefficients of determination of 0.61 and 0.70, for predicting eGFRs defined by the MDRD and CKD-EPI formulae, respectively., Conclusions: We constructed and internally validated two nomograms to predict eGFRs at 1 year after PN, using only preoperative covariates as predictors.- Published
- 2017
- Full Text
- View/download PDF
50. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.
- Author
-
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, and Geynisman DM
- Subjects
- Aged, Benzimidazoles adverse effects, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell pathology, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Immunohistochemistry methods, Male, Middle Aged, Mutation, Mycobacterium bovis, Quinolones adverse effects, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Urothelium pathology, Benzimidazoles administration & dosage, Carcinoma, Transitional Cell drug therapy, Quinolones administration & dosage, Receptor, Fibroblast Growth Factor, Type 3 genetics, Urinary Bladder Neoplasms drug therapy
- Abstract
Purpose: To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population. Experimental Design: A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC ( > 2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or FGFR3 mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate. Results: Between 11/2013 and 10/2014, 13 patients enrolled (10 IHC+ Mut-, 3 IHC+ Mut+). Accrual ended prematurely due to cessation of dovitinib clinical development. Demographics included the following: median age 70 years; 85% male; carcinoma in situ (CIS; 3 patients), Ta/T1 (8 patients), and Ta/T1 + CIS (2 patients); median prior regimens 3. Toxicity was frequent with all patients experiencing at least one grade 3-4 event. Six-month CR rate was 8% (0% in IHC+ Mut-; 33% in IHC+ Mut+). The primary endpoint was not met. Pharmacodynamically active (94-5,812 nmol/L) dovitinib concentrations in urothelial tissue were observed in all evaluable patients. Reductions in pFGFR3 IHC staining were observed post-dovitinib treatment. Conclusions: Dovitinib consistently achieved biologically active concentrations within the urothelium and demonstrated pharmacodynamic pFGFR3 inhibition. These results support systemic administration as a viable approach to clinical trials in patients with NMIUC. Long-term dovitinib administration was not feasible due to frequent toxicity. Absent clinical activity suggests that patient selection by pFGFR3 IHC alone does not enrich for response to FGFR3 kinase inhibitors in urothelial carcinoma. Clin Cancer Res; 23(12); 3003-11. ©2016 AACR ., (©2016 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.